The earnings call presented a mixed picture. There were significant achievements, particularly with the strong performance and growth in the Integrity product line and the commercial channel. However, these positives were tempered by challenges such as the disappointing results of the Hyalofast trial, manufacturing issues impacting gross margin, and overall revenue decline. While there is optimism around future growth and product development, immediate challenges place the sentiment in balance.

Company Guidance -

Q3 2025

During Anika's second quarter 2025 conference call, the company reaffirmed its commitment to meeting its full-year guidance despite some challenges. The commercial channel is expected to grow between 12% and 18%, while the OEM channel is anticipated to decline by 16% to 20%. Adjusted EBITDA is projected to range from negative 3% to positive 3%. Anika reported a revenue decline of 8% for the quarter, primarily due to manufacturing challenges and reduced pricing from J&J. Despite these setbacks, regenerative solutions showed strong performance with a 41% growth, led by the Integrity Implant System. Gross margins are expected to improve in the second half to the 58%-59% range. Anika remains optimistic about its future, planning to submit its PMA for Hyalofast in the second half of the year and aiming for a commercial launch in 2027.

Integrity's Strong Performance

Integrity has already exceeded its full year 2024 performance and is on track to more than double in 2025, leading to 41% growth in Regenerative Solutions revenue this quarter.

Commercial Channel Growth

Regenerative solutions within the commercial channel delivered standout performance, growing 41% year-over-year driven by continued momentum in the Integrity Implant System.

Operating Expense Reduction

There was a 17% reduction in total operating expenses year-over-year, including a 22% decline in SG&A expenses.

Cingal Progress

Meaningful progress was made advancing the final steps toward NDA filing for Cingal, remaining on track to initiate the bioequivalence study by year-end.

Anika Therapeutics (ANIK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ANIK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.21 / -	-0.25	―	―	―
Jul 30, 2025	2025 (Q2)	-0.26 / -0.13	0.17	-176.47% (-0.30)
May 09, 2025	2025 (Q1)	-0.09 / -0.06	0.09	-166.67% (-0.15)
Mar 12, 2025	2024 (Q4)	-0.23 / -0.03	0.05	-160.00% (-0.08)
Oct 31, 2024	2024 (Q3)	0.09 / -0.25	0	―
Aug 08, 2024	2024 (Q2)	0.07 / 0.17	0.06	183.33% (+0.11)
May 08, 2024	2024 (Q1)	-0.08 / 0.09	-0.36	125.00% (+0.45)
Mar 13, 2024	2023 (Q4)	-0.23 / 0.05	-0.34	114.71% (+0.39)
Nov 02, 2023	2023 (Q3)	-0.35 / 0.00	-0.29	―
Aug 08, 2023	2023 (Q2)	-0.32 / 0.06	-0.2	130.00% (+0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ANIK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$11.16	$8.10	-27.42%
May 09, 2025	$14.74	$11.64	-21.03%
Mar 12, 2025	$17.11	$15.21	-11.10%
Oct 31, 2024	$24.68	$17.11	-30.67%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Anika Therapeutics (ANIK) report earnings?

Anika Therapeutics (ANIK) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Anika Therapeutics (ANIK) earnings time?

Anika Therapeutics (ANIK) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ANIK EPS forecast?

ANIK EPS forecast for the fiscal quarter 2025 (Q3) is -0.21.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing